Immunic Valuation
| IMUX Stock | USD 1.15 0.03 2.68% |
Today, the firm appears to be undervalued. Immunic retains a regular Real Value of $4.03 per share. The prevalent price of the firm is $1.15. Our model calculates the value of Immunic from evaluating the firm fundamentals such as Return On Equity of -2.16, shares owned by insiders of 1.03 %, and Return On Asset of -0.91 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Immunic's price fluctuation is relatively risky at this time. Calculation of the real value of Immunic is based on 3 months time horizon. Increasing Immunic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Immunic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunic Stock. However, Immunic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.15 | Real 4.03 | Hype 1.12 |
The intrinsic value of Immunic's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immunic's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immunic helps investors to forecast how Immunic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunic more accurately as focusing exclusively on Immunic's fundamentals will not take into account other important factors: Immunic Total Value Analysis
Immunic is currently anticipated to have valuation of 40.91 M with market capitalization of 104.49 M, debt of 1.33 M, and cash on hands of 72.77 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Immunic fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
40.91 M | 104.49 M | 1.33 M | 72.77 M |
Immunic Asset Utilization
One of the ways to look at asset utilization of Immunic is to check how much profit was generated for every dollar of assets it reports. Immunic retains a negative application of resources of -0.91 (percent), losing $0.00909 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Immunic shows how discouraging it operates for each dollar spent on its resources.Immunic Ownership Allocation
Immunic has a total of 90.08 Million outstanding shares. Over half of Immunic's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Immunic Profitability Analysis
Net Loss for the year was (93.61 M) with profit before overhead, payroll, taxes, and interest of 0.About Immunic Valuation
Our relative valuation model uses a comparative analysis of Immunic. We calculate exposure to Immunic's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immunic's related companies.Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.
Immunic Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 44.3 M |
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.